Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma

Targeted and immunotherapy regimens have revolutionized the treatment of advanced melanoma patients. Despite this, only a subset of patients respond durably. Recently, combination strategies of BRAF/MEK inhibitors with immune checkpoint inhibitor monotherapy (α-CTLA-4 or α-PD-1) have increased the r...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Michael G., Szczepaniak Sloane, Robert, Witt, Russell G., Reuben, Alexandre, Gaudreau, Pierre Olivier, Andrews, Miles C., Feng, Ningping, Johnson, Sarah, Class, Caleb A., Bristow, Christopher, Wani, Khalida, Hudgens, Courtney, Nezi, Luigi, Manzo, Teresa, De Macedo, Mariana Pettaccia, Hu, Jianhua, Davis, Richard, Jiang, Hong, Prieto, Peter, Burton, Elizabeth, Hwu, Patrick, Tawbi, Hussein, Gershenwald, Jeffrey, Lazar, Alexander J., Tetzlaff, Michael T., Overwijk, Willem, Woodman, Scott E, Cooper, Zachary A., Marszalek, Joseph R., Davies, Michael A., Heffernan, Timothy P., Wargo, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583008/
https://www.ncbi.nlm.nih.gov/pubmed/34777916
http://dx.doi.org/10.1080/2162402X.2021.1992880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583008/
https://www.ncbi.nlm.nih.gov/pubmed/34777916
http://dx.doi.org/10.1080/2162402X.2021.1992880

Ejemplares similares